<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/"><channel rdf:about="http://www.exphem.org/?rss=yes"><title>Experimental Hematology</title><description>Experimental Hematology RSS feed: Current Issue. 
 Experimental Hematology  publishes original research reports, reviews, letters to the editor, and abstracts of the annual meeting 

of the International Society for Experimental Hematology. We welcome manuscripts describing research involving in vivo and ex vivo 
studies in the following areas: cell cycle regulation, cytokines, erythropoiesis, gene therapy, general hematopoiesis, granulopoiesis, 
hematological malignancies, immunobiology, immunotherapy, lymphopoiesis, megakaryocytopoiesis, microenvironment, monocyte development, 
molecular genetics, signal transduction, stem cell biology, stem cell plasticity, and experimental as well as clinical stem cell transplantation.</description><link>http://www.exphem.org/?rss=yes</link><dc:publisher>Elsevier Inc.</dc:publisher><dc:language>en</dc:language><dc:rights> © 2010 Published by Elsevier Inc. All rights reserved. </dc:rights><prism:publicationName>Experimental Hematology</prism:publicationName><prism:issn>0301-472X</prism:issn><prism:volume>38</prism:volume><prism:number>3</prism:number><prism:publicationDate>March 2010</prism:publicationDate><prism:copyright> © 2010 Published by Elsevier Inc. All rights reserved. </prism:copyright><prism:rightsAgent>healthpermissions@elsevier.com</prism:rightsAgent><items><rdf:Seq><rdf:li rdf:resource="http://www.exphem.org/article/PIIS0301472X10000160/abstract?rss=yes"/><rdf:li rdf:resource="http://www.exphem.org/article/PIIS0301472X09004585/abstract?rss=yes"/><rdf:li rdf:resource="http://www.exphem.org/article/PIIS0301472X10000111/abstract?rss=yes"/><rdf:li rdf:resource="http://www.exphem.org/article/PIIS0301472X09004603/abstract?rss=yes"/><rdf:li rdf:resource="http://www.exphem.org/article/PIIS0301472X0900486X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.exphem.org/article/PIIS0301472X09004615/abstract?rss=yes"/><rdf:li rdf:resource="http://www.exphem.org/article/PIIS0301472X09004883/abstract?rss=yes"/><rdf:li rdf:resource="http://www.exphem.org/article/PIIS0301472X09004871/abstract?rss=yes"/><rdf:li rdf:resource="http://www.exphem.org/article/PIIS0301472X1000010X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.exphem.org/article/PIIS0301472X10000020/abstract?rss=yes"/></rdf:Seq></items></channel><item rdf:about="http://www.exphem.org/article/PIIS0301472X10000160/abstract?rss=yes"><title>Editorial Board</title><link>http://www.exphem.org/article/PIIS0301472X10000160/abstract?rss=yes</link><description></description><dc:title>Editorial Board</dc:title><dc:creator></dc:creator><dc:identifier>10.1016/S0301-472X(10)00016-0</dc:identifier><dc:source>Experimental Hematology 38, 3 (2010)</dc:source><dc:date>2010-03-01</dc:date><prism:publicationName>Experimental Hematology</prism:publicationName><prism:publicationDate>2010-03-01</prism:publicationDate><prism:volume>38</prism:volume><prism:number>3</prism:number><prism:issueIdentifier>S0301-472X(10)X0002-9</prism:issueIdentifier><prism:section></prism:section><prism:startingPage>IFC</prism:startingPage><prism:endingPage>IFC</prism:endingPage></item><item rdf:about="http://www.exphem.org/article/PIIS0301472X09004585/abstract?rss=yes"><title>CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia</title><link>http://www.exphem.org/article/PIIS0301472X09004585/abstract?rss=yes</link><description>Objective: Despite a fludarabine-based treatment is the first choice of therapy in chronic lymphocytic leukemia (CLL), not all patients achieve a partial or complete response and some of them develop autoimmune manifestations. The aim of this study was to evaluate the influence of CD154 on these adverse effects because CD154 is involved in both B-cell survival and autoimmunity.Materials and Methods: Peripheral blood mononuclear cells (PBMC) from 36 patients with CLL were cultured in vitro with fludarabine or 2-chlorodeoxyadenosine for 24, 48, and 72hours.Results: Seven patients (19.4%) presented CD154 expression in PBMC cultured with purine analogues in vitro for 24 and/or 48hours, while no expression was found when cultured in media alone. These seven patients showed a decreased apoptotic rate in vitro after purine analogues compared with those patients who did not express CD154 (p=0.01 for fludarabine; p&lt;0.001 for 2-chlorodeoxyadenosine). CD154 expression was found to have prognostic value for response to fludarabine in vivo and was associated with the development of autoimmune manifestations (odds ratio=25; 95% confidence interval=3.5−166.7; p&lt;0.001).Conclusion: Our preliminary results suggest that CD154 expression in CLL patients, which may be induced by purine analogues, is associated with resistance to fludarabine and with development of autoimmune manifestations.</description><dc:title>CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia</dc:title><dc:creator>Maria Jesus Citores, Raquel Castejon, Mercedes Villarreal, Silvia Rosado, Jose Antonio Garcia-Marco, Juan Antonio Vargas</dc:creator><dc:identifier>10.1016/j.exphem.2009.12.001</dc:identifier><dc:source>Experimental Hematology 38, 3 (2010)</dc:source><dc:date>2009-12-21</dc:date><prism:publicationName>Experimental Hematology</prism:publicationName><prism:publicationDate>2009-12-21</prism:publicationDate><prism:volume>38</prism:volume><prism:number>3</prism:number><prism:issueIdentifier>S0301-472X(10)X0002-9</prism:issueIdentifier><prism:section>Hematological Malignancies</prism:section><prism:startingPage>165</prism:startingPage><prism:endingPage>173</prism:endingPage></item><item rdf:about="http://www.exphem.org/article/PIIS0301472X10000111/abstract?rss=yes"><title>Extrinsic signals determine myeloid-erythroid lineage switch in MN1 leukemia</title><link>http://www.exphem.org/article/PIIS0301472X10000111/abstract?rss=yes</link><description>Objective: Transcriptional control of hematopoietic lineage fate relies on the integration of many intra- and extracellular signals. To test whether the microenvironment impacts on leukemic phenotype, we exploited the MN1 model of acute myeloid leukemia under defined genetically modified microenvironmental conditions.Materials and Methods: The requirement of both FLT3 and c-Kit signaling for MN1 leukemias was investigated using retroviral infection of bone marrow cells from wild-type, c-Kit–mutated (W41), and Flt3-ligand knockout cells, and bone marrow transplantation into wild-type, c-Kit–mutated, or Flt3-ligand knockout mice.Results: Genetic disruption of both FLT3 and c-Kit signaling in the MN1-leukemia model was dispensable for MN1-induced leukemogenesis. However, it induced a switch from myeloid to erythroid phenotype that was preserved, when FLT3 signaling was restored by secondary transplantation of leukemic cells into wild-type recipients.Conclusions: Our findings underscore the importance of microenvironmental signals for lineage choice in leukemia and identify signals that are important in myeloid-erythroid lineage decisions.</description><dc:title>Extrinsic signals determine myeloid-erythroid lineage switch in MN1 leukemia</dc:title><dc:creator>Michael Heuser, Gyeongsin Park, Yeonsook Moon, Tobias Berg, Ping Xiang, Florian Kuchenbauer, Sarah Vollett, Courteney Lai, R. Keith Humphries</dc:creator><dc:identifier>10.1016/j.exphem.2010.01.003</dc:identifier><dc:source>Experimental Hematology 38, 3 (2010)</dc:source><dc:date>2010-01-21</dc:date><prism:publicationName>Experimental Hematology</prism:publicationName><prism:publicationDate>2010-01-21</prism:publicationDate><prism:volume>38</prism:volume><prism:number>3</prism:number><prism:issueIdentifier>S0301-472X(10)X0002-9</prism:issueIdentifier><prism:section>Hematological Malignancies</prism:section><prism:startingPage>174</prism:startingPage><prism:endingPage>179</prism:endingPage></item><item rdf:about="http://www.exphem.org/article/PIIS0301472X09004603/abstract?rss=yes"><title>Impact of CXCR4 inhibition on FLT3-ITD−positive human AML blasts</title><link>http://www.exphem.org/article/PIIS0301472X09004603/abstract?rss=yes</link><description>Objective: Internal tandem duplication (ITD) mutations of the FLT3 receptor are associated with a high incidence of relapse in acute myeloid leukemia (AML). Expression of the CXCR4 receptor in FLT3-ITD−positive AML is correlated with poor outcome, and inhibition of CXCR4 was shown to sensitize AML blasts toward chemotherapy. The aim of this study was to evaluate the impact of FLT3-ITD on cell proliferation and CXCR4-dependent migration in human hematopoietic progenitor cells and to investigate their response to CXCR4 inhibition.Materials and Methods: We used primary blasts from patients with FLT3-ITD or FLT3 wild-type AML. In addition, human CD34+ hematopoietic progenitor cells were transduced to &gt;70% with retroviral vectors containing human FLT3-ITD.Results: We found that FLT3-ITD transgene overexpressing human hematopoietic progenitor cells show strongly reduced migration toward stromal-derived factor−1 in vitro and display significantly reduced bone marrow homing in nonobese diabetic severe combined immunodeficient mice. Cocultivation of FLT3-ITD−positive AML blasts or hematopoietic progenitor cells on bone marrow stromal cells resulted in a strong proliferation advantage and increased early cobblestone area−forming cells compared to FLT3−wild-type AML blasts. Addition of the CXCR4 inhibitor AMD3100 to the coculture significantly reduced both cobblestone area−forming cells and proliferation of FLT3-ITD−positive cells, but did not affect FLT3−wild-type cells—highlighting the critical interaction between CXCR4 and FLT3-ITD.Conclusion: CXCR4 inhibition to decrease cell proliferation and to control the leukemic burden may provide a novel therapeutic strategy in patients with advanced FLT3-ITD−positive AML.</description><dc:title>Impact of CXCR4 inhibition on FLT3-ITD−positive human AML blasts</dc:title><dc:creator>Angela Jacobi, Sebastian Thieme, Romy Lehmann, Fernando Ugarte, Harry L. Malech, Sina Koch, Christian Thiede, Katrin Müller, Martin Bornhäuser, Martin Ryser, Sebastian Brenner</dc:creator><dc:identifier>10.1016/j.exphem.2009.12.003</dc:identifier><dc:source>Experimental Hematology 38, 3 (2010)</dc:source><dc:date>2009-12-25</dc:date><prism:publicationName>Experimental Hematology</prism:publicationName><prism:publicationDate>2009-12-25</prism:publicationDate><prism:volume>38</prism:volume><prism:number>3</prism:number><prism:issueIdentifier>S0301-472X(10)X0002-9</prism:issueIdentifier><prism:section>Hematological Malignancies</prism:section><prism:startingPage>180</prism:startingPage><prism:endingPage>190</prism:endingPage></item><item rdf:about="http://www.exphem.org/article/PIIS0301472X0900486X/abstract?rss=yes"><title>Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways</title><link>http://www.exphem.org/article/PIIS0301472X0900486X/abstract?rss=yes</link><description>Objective: Eriocalyxin B (EriB) is a natural diterpenoid purified from Isodon eriocalyx var. laxiflora and possesses strong antileukemic activity. In this study, we further investigated its effect and mechanism of action in human lymphoma.Materials and Methods: In vitro, a series of B- and T-lymphoma cells were treated with EriB. Cell apoptosis was analyzed using flow cytometric assay. Expression of proteins related to apoptosis and cell signal transduction were assessed using Western blot. In vivo antitumor activity of EriB was examined in murine xenograft B- and T-lymphoma models, with in situ cell apoptosis detected by terminal deoxytransferase-catalyzed DNA nick-end labeling assay.Results: EriB significantly inhibited lymphoma cell proliferation and induced apoptosis in association with caspase activation. Antiapoptotic Bcl-2 family members Bcl-2 and Bcl-xL were downregulated, with proapoptotic member Bax stable or upregulated, resulting in reduced Bcl-2/Bax and Bcl-xL/Bax ratios. Meanwhile, multiple signal transduction pathways were involved in lymphoma cell apoptosis in response to EriB, including inhibition of nuclear factor (NF)-κB and AKT pathways, and the activation of extracellular signal-related kinase (ERK) pathway. AKT inactivation was related to increased expression of cyclin-dependent kinase inhibitor P21, decreased expression of antiapoptotic phosphorylated form of Bad, and NF-κB activator IκB kinase α/β. ERK activation corresponded to reactive oxygen species production and could be blocked by antioxidant dithiothreitol. In murine xenograft lymphoma models, EriB remarkably inhibited tumor growth and induced in situ tumor cell apoptosis.Conclusion: These findings broaden the value of EriB as a promising candidate targeting apoptosis cascade in treatment of hematological malignancies.</description><dc:title>Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways</dc:title><dc:creator>Yi-Wen Zhang, Xiao-Xing Jiang, Qiu-Sheng Chen, Wen-Yu Shi, Lan Wang, Han-Dong Sun, Zhi-Xiang Shen, Zhu Chen, Sai-Juan Chen, Wei-Li Zhao</dc:creator><dc:identifier>10.1016/j.exphem.2009.12.005</dc:identifier><dc:source>Experimental Hematology 38, 3 (2010)</dc:source><dc:date>2010-01-04</dc:date><prism:publicationName>Experimental Hematology</prism:publicationName><prism:publicationDate>2010-01-04</prism:publicationDate><prism:volume>38</prism:volume><prism:number>3</prism:number><prism:issueIdentifier>S0301-472X(10)X0002-9</prism:issueIdentifier><prism:section>Hematological Malignancies</prism:section><prism:startingPage>191</prism:startingPage><prism:endingPage>201</prism:endingPage></item><item rdf:about="http://www.exphem.org/article/PIIS0301472X09004615/abstract?rss=yes"><title>Abnormalities of the αβ T-cell receptor repertoire in advanced myelodysplastic syndrome</title><link>http://www.exphem.org/article/PIIS0301472X09004615/abstract?rss=yes</link><description>Objective: Analysis of the αβ T-cell receptor (TCR) repertoire in patients with myelodysplastic syndrome (MDS) using the technique of TCR β-chain spectratyping has provided valuable insight into the pathophysiology of cytopenias in a subset of patients with this heterogeneous disorder. TCR β-chain spectratypes are complex data sets, however, and statistical tools for their comprehensive analysis are limited. The objective of the present work was to develop a method to enable quantitative evaluation and global comparison of spectratype data from different individuals and to study the prevalence of TCR β repertoire abnormalities in MDS patients.Materials and Methods: We developed a robust statistical method based on k-means clustering analysis, and applied this method to analysis of the αβ TCR repertoires in 50 MDS patients and 23 age-matched healthy controls.Results: Cluster analysis identified a subset of 11 MDS patients with profoundly abnormal αβ TCR repertoires. This group of patients was characterized by advanced disease by International Prognostic Scoring System and World Health Organization criteria, increased expression of the Wilms' tumor-1 oncogene, increased bone marrow myeloblast count, and older age.Conclusions: We have developed a robust analytic algorithm that enables the comparison of αβ TCR repertoires between individuals and have shown that abnormal αβ TCR repertoire is a feature of a subset of patients with advanced MDS.</description><dc:title>Abnormalities of the αβ T-cell receptor repertoire in advanced myelodysplastic syndrome</dc:title><dc:creator>Paulo V. Campregher, Santosh K. Srivastava, H. Joachim Deeg, Harlan S. Robins, Edus H. Warren</dc:creator><dc:identifier>10.1016/j.exphem.2009.12.004</dc:identifier><dc:source>Experimental Hematology 38, 3 (2010)</dc:source><dc:date>2009-12-25</dc:date><prism:publicationName>Experimental Hematology</prism:publicationName><prism:publicationDate>2009-12-25</prism:publicationDate><prism:volume>38</prism:volume><prism:number>3</prism:number><prism:issueIdentifier>S0301-472X(10)X0002-9</prism:issueIdentifier><prism:section>Immunobiology</prism:section><prism:startingPage>202</prism:startingPage><prism:endingPage>212</prism:endingPage></item><item rdf:about="http://www.exphem.org/article/PIIS0301472X09004883/abstract?rss=yes"><title>B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression</title><link>http://www.exphem.org/article/PIIS0301472X09004883/abstract?rss=yes</link><description>Objective: Antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells is a major effector mechanism of the monoclonal anti-CD20 antibody rituximab in eliminating B-cell lymphomas. Resistance to this treatment occurs, although CD20 antigen is expressed on the tumor cells.Materials and Methods: A model of ADCC was established by stimulating human bulk NK cells and inhibitory killer immunoglobulin receptor (KIR)−defined NK cells from human leukocyte antigen (HLA)−typed donors. NK-cell activation was triggered via stimulation of the Fc receptor with immunoglobulin G aggregates, rituximab-labeled HLA-defined CD20-positive B-lymphoblast cell lines or CD20-positive B-lymphoma cell lines. The effect of KIR ligation by anti-KIR antibodies and HLA, the HLA expression density and rituximab concentrations on the efficacy of ADCC were analyzed in granzyme B ELISPOT measuring NK-cell activation and fluorescein-activated cell sorting cytotoxicity assay.Results: HLA, but not CD20 expression density correlated with NK-cell activity against rituximab-labeled targets. ADCC was increased or decreased following HLA shielding or KIR activation by anti-KIR antibodies, respectively. Herein we show that rituximab-induced ADCC is attenuated upon ligation of KIR by HLA molecules expressed on human B-lymphoma target cells. Moreover, anti-KIR antibodies do not only block KIR/HLA interactions, but display agonistic effects at the KIR, which has to be considered for therapeutical applications.Conclusion: KIR activation and HLA expression density are critical determinants for the efficacy of rituximab treatment. An explanation for the failure of rituximab treatment may be the protection of the tumor cells from ADCC by inhibiting NK-cell function with their surface HLA.</description><dc:title>B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression</dc:title><dc:creator>Andrea Borgerding, Justin Hasenkamp, Michael Engelke, Nina Burkhart, Lorenz Trümper, Jürgen Wienands, Bertram Glass</dc:creator><dc:identifier>10.1016/j.exphem.2009.12.007</dc:identifier><dc:source>Experimental Hematology 38, 3 (2010)</dc:source><dc:date>2010-01-06</dc:date><prism:publicationName>Experimental Hematology</prism:publicationName><prism:publicationDate>2010-01-06</prism:publicationDate><prism:volume>38</prism:volume><prism:number>3</prism:number><prism:issueIdentifier>S0301-472X(10)X0002-9</prism:issueIdentifier><prism:section>Immunotherapy</prism:section><prism:startingPage>213</prism:startingPage><prism:endingPage>221</prism:endingPage></item><item rdf:about="http://www.exphem.org/article/PIIS0301472X09004871/abstract?rss=yes"><title>Auto-reconstitution of the T-cell compartment by radioresistant hematopoietic cells following lethal irradiation and bone marrow transplantation</title><link>http://www.exphem.org/article/PIIS0301472X09004871/abstract?rss=yes</link><description>Objective: In lethally irradiated bone marrow chimeras, part of the reconstituted T-cell compartment is derived from the irradiated host, but the detailed origin and functional activity of host-derived T cells has not been thoroughly analyzed. Herein, we determine the origin and function of radioresistant host-derived T cells.Materials and Methods: Lethally irradiated thymectomized or nonthymectomized C57BL/6 host mice were reconstituted with syngeneic bone marrow, itself incapable of generating T cells. Using fetal thymic organ cultures, bulk and limiting dilution assays on OP9-DL1 stromal cells, unambiguous cohorts of thymus-derived and peripheral T-cell−derived T cells were phenotypically characterized by flow cytometry and functionally characterized by their ability to participate in a T-cell−dependent antibody response.Results: Both thymus-derived and peripheral T-cell−derived host T cells are functional and can reconstitute 35% of the normal T-cell pool. By comparing thymectomized vs nonthymectomized hosts, host-derived T cells were shown to comprise a major (70%) subpopulation of de novo generated, thymus-derived, polyclonal, naïve cells, and a minor subpopulation of surviving, peripheral, oligoclonal, memory-like cells. Unlike euthymic recipients, mice whose T cells were derived from surviving peripheral T cells were frequently incapable of mounting a T-cell−dependent antibody response. Host-derived thymocytes regenerated in an interleukin-7−dependent fashion from conventional DN2 thymocytes and their differentiation recapitulated normal thymic ontogeny.Conclusion: We characterized, for the first time, functional radioresistant DN2-phenotype thymic T-cell precursors, the T-cell progeny of which might provide a first line of defense against infections during the lymphopenic phase post−bone marrow transplantation.</description><dc:title>Auto-reconstitution of the T-cell compartment by radioresistant hematopoietic cells following lethal irradiation and bone marrow transplantation</dc:title><dc:creator>Nabil Bosco, Lee Kim Swee, Angèle Bénard, Rhodri Ceredig, Antonius Rolink</dc:creator><dc:identifier>10.1016/j.exphem.2009.12.006</dc:identifier><dc:source>Experimental Hematology 38, 3 (2010)</dc:source><dc:date>2010-01-04</dc:date><prism:publicationName>Experimental Hematology</prism:publicationName><prism:publicationDate>2010-01-04</prism:publicationDate><prism:volume>38</prism:volume><prism:number>3</prism:number><prism:issueIdentifier>S0301-472X(10)X0002-9</prism:issueIdentifier><prism:section>Lymphopoiesis</prism:section><prism:startingPage>222</prism:startingPage><prism:endingPage>232.e2</prism:endingPage></item><item rdf:about="http://www.exphem.org/article/PIIS0301472X1000010X/abstract?rss=yes"><title>Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription</title><link>http://www.exphem.org/article/PIIS0301472X1000010X/abstract?rss=yes</link><description>Objective: Microvesicles have been shown to mediate intercellular communication. Previously, we have correlated entry of murine lung-derived microvesicles into murine bone marrow cells with expression of pulmonary epithelial cell-specific messenger RNA (mRNA) in these marrow cells. The present studies establish that entry of lung-derived microvesicles into marrow cells is a prerequisite for marrow expression of pulmonary epithelial cell-derived mRNA.Materials and Methods: Murine bone marrow cells cocultured with rat lung, but separated from them using a cell-impermeable membrane (0.4-μm pore size), were analyzed using species-specific primers (for rat or mouse).Results: These studies revealed that surfactant B and C mRNA produced by murine marrow cells were of both rat and mouse origin. Similar results were obtained using murine lung cocultured with rat bone marrow cells or when bone marrow cells were analyzed for the presence of species-specific albumin mRNA after coculture with rat or murine liver. These studies show that microvesicles both deliver mRNA to marrow cells and mediate marrow cell transcription of tissue-specific mRNA. The latter likely underlies the longer-term stable change in genetic phenotype that has been observed. We have also observed microRNA in lung-derived microvesicles, and studies with RNase-treated microvesicles indicate that microRNA negatively modulates pulmonary epithelial cell-specific mRNA levels in cocultured marrow cells. In addition, we have also observed tissue-specific expression of brain, heart, and liver mRNA in cocultured marrow cells, suggesting that microvesicle-mediated cellular phenotype change is a universal phenomena.Conclusion: These studies suggest that cellular systems are more phenotypically labile than previously considered.</description><dc:title>Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription</dc:title><dc:creator>Jason M. Aliotta, Mandy Pereira, Kevin W. Johnson, Nicole de Paz, Mark S. Dooner, Napoleon Puente, Carol Ayala, Kate Brilliant, David Berz, David Lee, Bharat Ramratnam, Paul N. McMillan, Douglas C. Hixson, Djuro Josic, Peter J. Quesenberry</dc:creator><dc:identifier>10.1016/j.exphem.2010.01.002</dc:identifier><dc:source>Experimental Hematology 38, 3 (2010)</dc:source><dc:date>2010-01-15</dc:date><prism:publicationName>Experimental Hematology</prism:publicationName><prism:publicationDate>2010-01-15</prism:publicationDate><prism:volume>38</prism:volume><prism:number>3</prism:number><prism:issueIdentifier>S0301-472X(10)X0002-9</prism:issueIdentifier><prism:section>Stem Cell Biology</prism:section><prism:startingPage>233</prism:startingPage><prism:endingPage>245</prism:endingPage></item><item rdf:about="http://www.exphem.org/article/PIIS0301472X10000020/abstract?rss=yes"><title>Human embryonic stem cell−derived vascular progenitor cells capable of endothelial and smooth muscle cell function</title><link>http://www.exphem.org/article/PIIS0301472X10000020/abstract?rss=yes</link><description>Objective: Previous studies have demonstrated development of endothelial cells (ECs) and smooth muscle cells (SMCs) as separate cell lineages derived from human embryonic stem cells (hESCs). We demonstrate CD34+ cells isolated from differentiated hESCs function as vascular progenitor cells capable of producing both ECs and SMCs. These studies better define the developmental origin and reveal the relationship between these two cell types, as well as provide a more complete biological characterization.Materials and Methods: hESCs are cocultured on M2-10B4 stromal cells or Wnt1-expressing M2-10B4 for 13 to 15 days to generate a CD34+ cell population. These cells are isolated using a magnetic antibody separation kit and cultured on fibronectin-coated dishes in EC medium. To induce SMC differentiation, culture medium is changed and a morphological and phenotypic change occurs within 24 to 48hours.Results: CD34+ vascular progenitor cells give rise to ECs and SMCs. The two populations express respective cell-specific transcripts and proteins, exhibit intracellular calcium in response to various agonists, and form robust tube-like structures when cocultured in Matrigel. Human umbilical vein endothelial cells cultured under SMC conditions do not exhibit a change in phenotype or genotype. Wnt1-overexpressing stromal cells produced an increased number of progenitor cells.Conclusions: The ability to generate large numbers of ECs and SMCs from a single vascular progenitor cell population is promising for therapeutic use to treat a variety of diseased and ischemic conditions. The stepwise differentiation outlined here is an efficient, reproducible method with potential for large-scale cultures suitable for clinical applications.</description><dc:title>Human embryonic stem cell−derived vascular progenitor cells capable of endothelial and smooth muscle cell function</dc:title><dc:creator>Katherine L. Hill, Petra Obrtlikova, Diego F. Alvarez, Judy A. King, Susan A. Keirstead, Jeremy R. Allred, Dan S. Kaufman</dc:creator><dc:identifier>10.1016/j.exphem.2010.01.001</dc:identifier><dc:source>Experimental Hematology 38, 3 (2010)</dc:source><dc:date>2010-01-11</dc:date><prism:publicationName>Experimental Hematology</prism:publicationName><prism:publicationDate>2010-01-11</prism:publicationDate><prism:volume>38</prism:volume><prism:number>3</prism:number><prism:issueIdentifier>S0301-472X(10)X0002-9</prism:issueIdentifier><prism:section>Stem Cell Biology</prism:section><prism:startingPage>246</prism:startingPage><prism:endingPage>257.e1</prism:endingPage></item></rdf:RDF>